The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for blockbuster treatments and impressive returns is clear, the connected risks are also notable. Many of